AXSM (Axsome Therapeutics) Quality Rank


AXSM Axsome Therapeutics Inc AXSM
52 GF Score
Price $244.77
GF Value $220.41
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Axsome Therapeutics Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Axsome Therapeutics Quality Rank Related Terms

AXSM
52GF Score
Axsome Therapeutics Inc AXSM
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Axsome Therapeutics (AXSM) Overvalued in 2026?

Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued. The current stock price of $244.77 is trading 11.1% above its estimated GF Value™ of $220.41. GuruFocus considers Axsome Therapeutics to be Modestly Overvalued.

Key valuation signals for AXSM:

  • Quality Rank:
  • GF Value™: $220.41 vs. price of $244.77 (11.1% above fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the AXSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Axsome Therapeutics Business Description

Address One World Trade Center, 29th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
52GF Score

Get the complete analysis for AXSM

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$244.77
Price
$220.41
GF Value